The First AI-Powered Myeloma Chatbot, and a New Clinical Trials Finder!


Why Advocacy Matters for Myeloma Patients: A Call to Action Just as many industries have lobbyists, myeloma patients need someone advocating for their needs as well. That’s why Danielle Doheny, the IMF’s Director of Public Policy and Advocacy, works on behalf of multiple myeloma patients as a federal lobbyist. In this blog, Danielle explains why advocacy is so important and how individuals can get involved. She also outlines some crucial Medicare changes that can directly impact patients. Read the full blog to learn more.


There’s Still Time to Make Your Impact This Blood Cancer Awareness Month This Blood Cancer Awareness Month, we ask, “Do you #kNOw myeloma?” Explore the IMF’s Blood Cancer Awareness Month website for infographics on myeloma facts, research breakthroughs in myeloma treatment, and inspirational stories of hope and resilience from those living with the disease. We encourage you to download them from the IMF’s social media tool kit and share them on social media while using the hashtag #kNOwMyeloma.


International Myeloma Foundation Launches Myelo: The First AI-Powered Responsive Chatbot to Provide Compassionate Myeloma Support The International Myeloma Foundation (IMF) is proud to announce the launching of Myelo—the first AI-powered responsive chatbot designed to act as the IMF’s virtual assistant for patients, care partners, and healthcare professionals. To get started chatting with Myelo, visit the IMF Myelo FAQ page. Read the full press release to learn more.


The IMF Partners with SparkCures to Help You Find Clinical Trials The IMF has partnered with SparkCures to help patients and care partners discover and explore eligible clinical trials across the U.S. We encourage you to visit this clinical trials finder on our website and create your free account. Our system evaluates your criteria against every clinical trial running around the U.S. We take the complex criteria and provide you with results that are personalized to your unique needs and preferences. Click the button to find a clinical trial.


Reserve Your Seat for the M-Power Richmond Community Workshop Sign up for Richmond community event to discuss health empowerment on Thursday, October 10, from 5:30-7:30 p.m. EST at the Ebenezer Baptist Church (216 W Leigh St., Richmond, VA 23220). We will focus on awareness of multiple myeloma in the African American community. The panel will share patient stories and suggestions to “M-Power” yourself if you are ever faced with a complicated diagnosis. Refreshments will be provided. Seating is limited, so register today!


Impact of Relapses, Stem Cell Transplants, Diet and Nutrition: Answering Your Myeloma Questions In this video, Dr. Joseph Mikhael, Chief Medical Officer of the International Myeloma Foundation, answers your top questions about multiple myeloma in this informative Q&A session. From stem cell transplants to multiple myeloma diet recommendations, Dr. Joe provides expert insights to help patients and caregivers navigate this complex disease.


Sign Up for a Virtual Regional Community Workshop Serving the Needs of the Northeastern Myeloma Communities Sign up for a Virtual Regional Community Workshop on Tuesday, October 8, from 5:30 p.m. to 8:30 p.m. EST, servicing the needs of those in New England. Speakers include Joseph Mikhael, IMF Chief Medical Officer MD, MEd, FRCPC, FACP (TGen at the City of Hope — Phoenix); Monique Hartley-Brown, MD, MMSc (Dana-Farber Cancer Insitute — Boston); and Kevin Brigle, PhD, ANP (VCU Massey Comprehensive Cancer Center — Richmond, VA). The workshop is FREE, but you will still need to register to participate.


Around the Web: Myeloma News To keep you abreast of the most recent myeloma research findings, “The Myeloma Minute” features links to top myeloma content around the web. Recently, European Society of Medical Oncology (ESMO) Congress published the article “CAR T Reduces All-Cause Mortality Greater Than a Bispecific Antibody in MM.” For guidance with Medicare, visit this handbook from Medicare.gov. Also, review summaries of the most fascinating myeloma research studies from this past month at the following link: August 2024 – Myeloma News from the Journals. As always, we invite you to visit the IMF Newsroom for the latest myeloma news.

Week in Review Blogs by Dr. Durie

Ask Dr. Durie Videos

Online Patient Forum

Smart Patients: Join the Conversation

Clinical Trial Fact Sheets

KTX-1001 (phase I trial – Now Accruing)

Phase II Relapsed or Refractory Venetoclax Trial (Fully Accrued)

CANOVA Trial (Fully Accrued)

Phase I/II Trial Using a Venetoclax Combination With or Without Bortezomib (Fully Accrued)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)

Upcoming Events

Register Now
6th Annual Inland Empire In-Person/Virtual Walk for Myeloma Miracles

Register Now
8th Annual Walkathon & BBQ to End Multiple Myeloma

Register Now
6th Annual Schleicher's Hikers 5K Run/Walk

Register Now
Amplify Black Myeloma Voices Virtual 5K

See also, all of our events.

We Thank Our Sponsors:

Abbvie Inc., GSK, Johnson & Johnson, Karyopharm Therapeutics, Regeneron, and Sanofi

We also thank individuals like you for your continued support!

Join the conversation at The International Myeloma Foundation

Facebook: /Myeloma | Twitter @IMFMyeloma | Instagram @IMFmyeloma

www.myeloma.org

This email was sent to by:
The International Myeloma Foundation
4400 Coldwater Canyon Ave., Suite 300
Studio City, CA 91604
Connect with the IMF InfoLine
1-800-452-2873

We respect your privacy and your preferences for communications of this nature.
Home • Unsubscribe • Manage Subscriptions • Privacy Policy

View as web page